Pennsylvania is currently home to 3457 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931
Recruiting
The primary objective of this study is to assess the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the composite endpoint of all-cause mortality (ACM) and total cardiovascular (CV) clinical events.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/15/2024
Locations: Research Site, Danville, Pennsylvania
Conditions: Transthyretin Amyloid Cardiomyopathy
Register for Updates
ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673
Recruiting
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP Substudy 1 (Phase 2) will evaluate efficacy and dose response of ACP-204 30 and 60 mg vs placebo. This substudy will be initiated first. Substudies 2A and 2B (both: Phase 3) will be confirmatory studies of either both doses (ACP-204 30 and 60 mg, respectively) or a single dose from Part 1 vs placebo. Substudies 2A and 2B will b... Read More
Gender:
All
Ages:
Between 55 years and 95 years
Trial Updated:
04/15/2024
Locations: Abington Neurological Associates, Abington, Pennsylvania
Conditions: Alzheimer's Disease Psychosis
Register for Updates
A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT
NCT06149403
Recruiting
A multi-center randomized clinical trial to compare OTL-203 (gene therapy) with stem cell transplant (standard of care) in patients with MPS-IH (Hurler syndrome).
Gender:
All
Ages:
Between 28 days and 30 months
Trial Updated:
04/15/2024
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: MPS-IH (Hurler Syndrome)
Register for Updates
Burn Pivotal Study
NCT06131203
Recruiting
The purpose of this study is to validate the algorithm for burn healing assessment by the Spectral MD DeepView device which would provide burn healing potential assessment.
Gender:
All
Ages:
All
Trial Updated:
04/15/2024
Locations: St. Christopher's Children Hospital, Philadelphia, Pennsylvania
Conditions: Burns, Wound Heal, Wounds and Injuries
Register for Updates
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
NCT06109311
Recruiting
The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or SGLT-2 (sodium-glucose cotransporter-2) inhibitor. The study will last about 46 weeks and may include up to 20 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Frontier Clinical Research, LLC, Scottdale, Pennsylvania
Conditions: Type 2 Diabetes
Register for Updates
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864
Recruiting
This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have cardiovascular or chronic kidney disease. People who have at least 2 health problems related to their weight or risks of cardiovascular disease can participate. Participants must have previously tried to lose weight by changing their diet. The purpose of this study is to find out whether people with overweight or obesity who take a medicine called su... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Heritage Valley Medical Group, Beaver, Pennsylvania
Conditions: Obesity
Register for Updates
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD
NCT06075095
Recruiting
The purpose of this study is to demonstrate that the lung function effect from orally inhaled BGF delivered via HFO propellant is equivalent to the lung function effect from orally inhaled BGF delivered via HFA propellant in participants with COPD. The study duration for each participant will be approximately 15 to 16 weeks and consist of: A screening and placebo run-in period of approximately 2 weeks prior to first dosing Three treatment periods of approximately 4 weeks each (one period for ea... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
04/15/2024
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
NCT06074562
Recruiting
The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Suburban Research Associates, West Chester, Pennsylvania
Conditions: Diabetic Peripheral Neuropathy
Register for Updates
A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus
NCT06056024
Recruiting
This study is open to adults with advanced cancer in the stomach and oesophagus. This is a study for people for whom previous treatment was not successful or no treatment exists. In this study, BI 3706674 is given to humans for the first time. The purpose of this study is to find a suitable dose of BI 3706674 that people with advanced cancer can tolerate when taken alone. Another purpose is to check whether BI 3706674 can make tumours shrink. BI 3706674 blocks growth signals and may prevent the... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Solid Tumor, KRAS Mutation
Register for Updates
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06046729
Recruiting
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/15/2024
Locations: DermDox Centers for Dermatology Loc. 17, Camp Hill, Pennsylvania
Conditions: Hidradenitis Suppurativa
Register for Updates
Optimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach
NCT05980260
Recruiting
This clinical trial will help us learn more about how to best care for babies with Neonatal Opioid Withdrawal Syndrome, also called NOWS. Babies with NOWS often have tremors, a hard time sleeping, excessive crying, and trouble feeding. Some babies that have NOWS need medicine. Doctors have two ways of providing medicine that are widely used today: Scheduled opioid taper approach. The baby gets medicine at regular times. As symptoms get better, the amount of medicine the baby gets decreases unti... Read More
Gender:
All
Ages:
Between 1 hour and 48 hours
Trial Updated:
04/15/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Neonatal Opiate Withdrawal Syndrome
Register for Updates
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
NCT05971940
Recruiting
The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair, Pittsburgh, Pennsylvania
Conditions: Type 2 Diabetes
Register for Updates